• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4600962)   Today's Articles (103)   Subscriber (49361)
For: Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, García-Laraña J, Bengoechea E, Martín A, Mediavilla JD, Palomera L, de Arriba F, González Y, Hernández JM, Sureda A, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Cibeira MT, Ramos MLM, Vidriales MB, Paiva B, Montalbán MA, Lahuerta JJ, Bladé J, Miguel JFS. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010;11:934-41. [PMID: 20739218 DOI: 10.1016/s1470-2045(10)70187-x] [Citation(s) in RCA: 381] [Impact Index Per Article: 27.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Number Cited by Other Article(s)
351
Sarasquete ME, Gutiérrez NC, Misiewicz-Krzeminska I, Paiva B, Chillón MC, Alcoceba M, García-Sanz R, Hernández JM, González M, San-Miguel JF. Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. Haematologica 2010;96:468-71. [PMID: 21160068 DOI: 10.3324/haematol.2010.033845] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]  Open
352
Harousseau JL. Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2010;10:424-42. [DOI: 10.3816/clml.2010.n.076] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
353
Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kropff M, Spicka I, Palumbo A, Wu KL, Esseltine DL, Liu K, Deraedt W, Cakana A, Van De Velde H, San Miguel JF. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 2010;86:23-31. [DOI: 10.1111/j.1600-0609.2010.01533.x] [Citation(s) in RCA: 105] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
354
Richards L. Hematology: Reduced-intensity induction therapy for elderly patients with multiple myeloma. Nat Rev Clin Oncol 2010;7:612. [PMID: 21049575 DOI: 10.1038/nrclinonc.2010.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
355
Maffucci JA, Walker DM, Ikegami A, Woller MJ, Gore AC. NMDA receptor subunit NR2b: effects on LH release and GnRH gene expression in young and middle-aged female rats, with modulation by estradiol. Neuroendocrinology 2008;87:129-41. [PMID: 18025808 PMCID: PMC2671961 DOI: 10.1159/000111136] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2007] [Accepted: 10/09/2007] [Indexed: 11/19/2022]
PrevPage 8 of 8 1245678Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA